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Circulating B lymphocytes are the major reservoir of
KSHV infection in infected subjects. However, B cell lines
and primary B cells are resistant to direct KSHV infection
in vitro. In addition, primary B cells are difficult to propa-
gate for more than a few days. In this study, we combined
a novel primary B cell propagation method with efficient
infection mediated by dendritic cells to study KSHV de
novo infection of primary B cells in vitro.
Primary monocyte-derived dendritic cells (MDDCs) or
plasmacytoid dendritic cells (pDCs) were pulsed with
KSHV for 4 hours at which point KSHV DNA was readily
detectable. Uptake of KSHV was significantly reduced by
pre-incubating cells with antibodies to integrins α3, β1
and DC-SIGN. Autologous B cells were grown on a feeder
layer of irradiated NIH3T3 cells transduced with a human
CD40L retroviral vector. KSHV+ DCs were co-cultivated
with primary B cells for 4–8 hours and then separated by
CD19+ immunomagnetic isolation. B cell cultures were
maintained on feeder cells for >30 days and monitored for
KSHV infection.
Efficient KSHV infection of primary B cells was mediated
by both MDDCs and pDCs. KSHV LANA protein (ORF73)
was detected by IFA in 2–15 percent of B cells through day
14. Viral gene expression analysis using a KSHV whole
genome virus array showed establishment of latent KSHV
infection followed by spontaneous reactivation of lytic
viral replication in the primary B cell cultures.
These studies suggest that dendritic cells play an impor-
tant role in the transmission and pathogenesis of KSHV in
infected subjects as well as demonstrating a powerful in
vitro model for studying KSHV infection of B cells.
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